Suchergebnisse - "Galli, Monica"

PubPharm (108)

1

A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma : The northern Italy experience

enthalten in: Cancer medicine | 2024

von Furlan, A. | Cea, M. | Pavan, L. | +25

2

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma : A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Oriol, A. | Dimopoulos, M. | Schjesvold, F. | +12

3

Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated BCMA surface density : A case report

enthalten in: British journal of haematology | 2024

von Cattaneo, I. | Valgardsdottir, R. | Cavagna, R. | +5

CommentIn: Br J Haematol. 2024 Feb;204(2):391-392. - PMID 38014717

4

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma : a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

enthalten in: Haematologica | 2024

von Gentile, M. | Vigna, E. | Palmieri, S. | +44

5

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma : The northern Italy experience

enthalten in: Cancer Medicine | 2024

von Furlan, A. | Cea, M. | Pavan, L. | +25

6

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

enthalten in: EClinicalMedicine | 2023

von Zamagni, E. | Oliva, S. | Gay, F. | +28

7

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients : real-world evidence from a propensity score matched analysis

enthalten in: Haematologica | 2023

von Mangiacavalli, S. | Cartia, C. | Galli, M. | +22

8

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

9

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

enthalten in: European journal of haematology | 2022

von Morabito, F. | Zamagni, E. | Conticello, C. | +41

10

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy : Analysis of 919 Cases Outside Clinical Trials

enthalten in: Frontiers in oncology | 2022

von Morabito, F. | Zamagni, E. | Conticello, C. | +45

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]